4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (D-) Rating at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by equities researchers at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

Several other brokerages have also recently issued reports on FDMT. Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Chardan Capital reduced their target price on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $26.71.

4D Molecular Therapeutics Stock Up 10.0 %

Shares of FDMT opened at $2.76 on Tuesday. The stock has a market cap of $127.79 million, a P/E ratio of -0.97 and a beta of 2.89. The business’s 50 day moving average price is $4.17 and its 200-day moving average price is $6.25. 4D Molecular Therapeutics has a 52 week low of $2.24 and a 52 week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $50,000. PNC Financial Services Group Inc. lifted its stake in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after acquiring an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $56,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.